Eton Pharmaceuticals (NASDAQ:ETON) launched IMPAVIDO (miltefosine) capsules in the United States under exclusive U.S. commercialization rights for the treatment of certain forms of leishmaniasis.
Pfizer (NYSE:PFE) announced it will present data from 45 oncology research abstracts at the European Society for Medical Oncology Congress 2026, taking place October 23–27 in Madrid, Spain.
Eli Lilly (NYSE:LLY) launched the Change the Course Commitment, an initiative aimed at increasing access to its diabetes and obesity medicines in resource-limited settings before 2040.
Kodiak Sciences (NASDAQ:KOD) reported that Zenkuda and tabirafusp-ted met primary vision endpoints in the Phase 3 DAYBREAK trial evaluating treatments for wet age-related macular degeneration.
Codexis (NASDAQ:CDXS) signed an agreement with an unnamed siRNA drug developer to explore stereo-defined fragment synthesis using its ECO Synthesis platform.
National Healthcare Properties (NYSE:NHP) agreed to sell 40 outpatient medical facilities for approximately $531 million, with closing expected in the fourth quarter of 2026.
MediciNova (NASDAQ:MNOV) reported topline results from a Phase 2 placebo-controlled trial evaluating MN-001, also known as tipelukast, in patients with type 2 diabetes, fatty liver disease, and elevated triglycerides.
Zymeworks (NASDAQ:ZYME) completed its acquisition of Theravance Biopharma for $17 per share, adding rights to YUPELRI profit sharing and international royalties.
IDEAYA Biosciences (NASDAQ:IDYA) promoted Dr. Michael White from chief scientific officer to president of research and development, effective September 28, 2026.
HUTCHMED (NASDAQ:HCM) initiated a global Phase Ia clinical trial of HMPL-A830 in patients with advanced solid tumors, with the first patient receiving a dose in China on September 24, 2026.
QIAGEN (NYSE:QGEN) received U.S. Food and Drug Administration clearance for its QIAstat-Dx BCID GN Plus AMR Panel, expanding access to its bloodstream infection testing portfolio for U.S. laboratories.
Tandem Diabetes Care (NASDAQ:TNDM) announced that Tandem Mobi, its automated insulin delivery system, is now available in 12 countries outside the United States, with the company accepting orders and shipping to eligible customers.
-640x360.webp&w=3840&q=75)
